期刊文献+

原位肝移植术中成分输血量评估 被引量:1

原文传递
导出
摘要 目的探讨各类终末期肝病患者进行原位肝脏移植时术中成分血用量。方法 85例肝脏移植患者根据原发病、术前血红蛋白水平及国际标准化比值(INR)进行分组,采用单变量分析的方法分析各变量与血液成分输注量的关系。结果肝移植术中平均成分输注量分别为悬浮红细胞11.09±8.47 U;新鲜冰冻血浆(8.76±7.48)U;冷沉淀(9.87±10.88)U;单采血小板(0.75±1.17)U。不同原发疾病间悬浮红细胞、冷沉淀及血小板输注量差异有统计学意义(P<0.05),但新鲜冰冻血浆输注量差异无统计学意义(P>0.05);术前血红蛋白异常与正常组间在悬浮红细胞和血小板用量上差异有统计学意义(P<0.05);术前INR异常组患者各种成分血用量明显高于INR正常组(P<0.05)。结论原发病、血红蛋白含量、术前INR可用于评估肝移植术中血液成分用量,指导临床输血实践。
出处 《医药论坛杂志》 2014年第3期100-101,共2页 Journal of Medical Forum
  • 相关文献

参考文献9

  • 1Liu LL, Niemann CU. Intraoperative management of liver trans- plant patients[ J]. Transplant Rev ,2011,25 ( 3 ) : 124-129.
  • 2Devi AS. Transfusion practice in orthotopic liver transplantation [J]. Indian J Crit Care Med,2009,13(3) :120-128.
  • 3Roullet S, Biais M, Millas E, et al. Risk factors for bleeding and transfusion during orthotopic liver transplantation [ J ]. Ann Fr Anesth Reanim,2011,30(4) :349.
  • 4Findlay JY, Fix OK, Pangam - Burtz C, et al. Critical care of the end - stage liver disease patient awaiting liver transplantation [ J ]. Liver Transpl, 2011,17 ( 5 ) :496.
  • 5张捷.肝移植治疗原发性肝癌的入选标准[J].昆明医学院学报,2012,33(1):1-2. 被引量:2
  • 6Sabate A, Dalmau A, Koo M, et al. Coagulopathy management in liver transplantation [ J ]. Transplant Proc, 2012,44 ( 6 ) : 1523- 1525.
  • 7Dasher K,Trotter JF. Intensive care unit management of liver - related coagulation disorders [ J ]. Crit Care Clin, 2012,28 ( 3 ) : 389-398.
  • 8Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease [ J ]. Clin Liver Dis,2009,13 ( 1 ) :21-31.
  • 9Nov - Padillo JA,Le6n - Justel A,Mellado - Miras P,et al. In- troduction of fibrinogen in the treatment of hemostatie disorders during orthotopie liver transplantation : implications in the use of allogenic blood[J]. Transplant Proe,2010,42(8) :2973-2974.

二级参考文献14

  • 1严律南.肝癌肝移植的现状与展望[J].中国医学科学院学报,2005,27(4):427-430. 被引量:9
  • 2樊嘉,周俭,徐泱,邱双健,吴志全,余耀,黄晓武,汤钊猷,王玉琦.肝癌肝移植适应证的选择:上海复旦标准[J].中华医学杂志,2006,86(18):1227-1231. 被引量:121
  • 3PARKIN D M,BRAY F,FERLAY J,et al.Estimating the world cancer burden:globocan2000[J].International Journal of Cancer,2001,94(2):153-156.
  • 4PARKIN D M,BRAY F,FERLAY J,et al.Global cancer statistics,2002[J].CA:a cancer journal for clinicians,2005,55(2):74-108.
  • 5TANG Z Y,YE S L,LIU Y K,et al.A decade's studies on metastasis of hepatocellular carcinoma[J].Journal of Cancer Research and Clinical Oncology,2004,130(4):187-196.
  • 6PAWARODE A,TANGKIJVANICH P,VORAVUD N.O-utcomes of primary hepatocellular carcinoma treatment:An 8 year experience with 368 patients in Thailand[J].Journal of Gastroenterology and Hepatology,2000,15(8):860-864.
  • 7MAZZAFERRO V,REGALIA E,DOCI R,et al.Liver tr-ansplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].New England Journal of Medicine,1996,334(11):693-700.
  • 8MAZZAFERRO V,LLOVET J M,MICELI R,et al.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria:a retrospective,exploratory analysis[J].The Lancet Oncology,2009,10(1):35-43.
  • 9MARSH J W,DVORCHIK I,BONHAM C A,et al.Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?[J].Cancer,2000,88(3):538-543.
  • 10YAO F Y,FERRELL L,BASS N M,et al.Liver transplantation for hepatocellular carcinoma:expansion of the tumor size limits does not adversely impact survival[J].Hepatology,2001,33(6):1 394-1 403.

共引文献1

  • 1王倩,陈俊,姚定康.肝癌肝移植[J].中华消化病与影像杂志(电子版),2014,4(6):19-23.

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部